Zoetis Inc. (NYSE:ZTS) Shares Sold by Copeland Capital Management LLC

Copeland Capital Management LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 95,810 shares of the company’s stock after selling 3,776 shares during the period. Copeland Capital Management LLC’s holdings in Zoetis were worth $18,719,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of ZTS. Webster Bank N. A. increased its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Quarry LP raised its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC bought a new stake in Zoetis during the 1st quarter valued at $43,000. Central Valley Advisors LLC bought a new position in shares of Zoetis in the second quarter worth $49,000. Finally, Future Financial Wealth Managment LLC bought a new position in shares of Zoetis in the first quarter worth $51,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 2.0 %

Shares of Zoetis stock opened at $189.45 on Tuesday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm has a market capitalization of $86.45 billion, a PE ratio of 36.50, a price-to-earnings-growth ratio of 3.00 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock’s fifty day moving average is $189.09 and its 200-day moving average is $177.34.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.41 earnings per share. Equities analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.91%. Zoetis’s payout ratio is currently 33.14%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZTS. Stifel Nicolaus upped their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.